For IndividualsFor Educators
ExpertMinds LogoExpertMinds
ExpertMinds

Ace your certifications with Practice Exams and AI assistance.

  • Browse Exams
  • For Educators
  • Blog
  • Privacy Policy
  • Terms of Service
  • Cookie Policy
  • Support
  • AWS SAA Exam Prep
  • PMI PMP Exam Prep
  • CPA Exam Prep
  • GCP PCA Exam Prep

© 2026 TinyHive Labs. Company number 16262776.

    PracticeACCAACCA FR — Financial Reporting Practice Exam 4Question 23
    Hard2 marksMultiple Choice
    Revenue from Contracts with CustomersIFRS 15RevenueLicensingSection B
    This question is part of a case study — click to read the full scenario(Case 21)

    Section B - Case 2: BioGenix

    Scenario: BioGenix is a biotechnology firm developing a new gene therapy, 'GeneX'. During the year ended 31 December 20X5, BioGenix incurred the following costs:

    • $2,000,000 on the research phase (Jan-Jun).
    • $3,000,000 on the development phase (Jul-Dec), incurred evenly over the 6 months.
      BioGenix management confirmed that the project met all IAS 38 capitalization criteria on 1 October 20X5.

    BioGenix also holds a patent for a different drug. On 1 January 20X5, BioGenix licensed this patent to PharmaCo. PharmaCo paid an upfront, non-refundable fee of $5,000,000 for the right to use the patent for 5 years. BioGenix has no further performance obligations. The contract also includes a $2,000,000 milestone payment if PharmaCo achieves $50m in sales in 20X5. By 31 December 20X5, PharmaCo's sales were $30m, and BioGenix determined it is highly probable the milestone will not be met.

    Finally, BioGenix has a Cash Generating Unit (CGU) that was impairment tested. Carrying amounts: Goodwill $1m, Patent $4m, Equipment $5m. Recoverable amount of the CGU is $7m.

    Question: How much of the 'GeneX' costs should be capitalized as an intangible asset for the year ended 31 December 20X5?

    View full case study page →

    ACCA · Question 23 · Revenue from Contracts with Customers

    Section B - Case 2: BioGenix

    Scenario: BioGenix is a biotechnology firm developing a new gene therapy, 'GeneX'. During the year ended 31 December 20X5, BioGenix incurred the following costs:

    • $2,000,000 on the research phase (Jan-Jun).
    • $3,000,000 on the development phase (Jul-Dec), incurred evenly over the 6 months.
      BioGenix management confirmed that the project met all IAS 38 capitalization criteria on 1 October 20X5.

    BioGenix also holds a patent for a different drug. On 1 January 20X5, BioGenix licensed this patent to PharmaCo. PharmaCo paid an upfront, non-refundable fee of $5,000,000 for the right to use the patent for 5 years. BioGenix has no further performance obligations. The contract also includes a $2,000,000 milestone payment if PharmaCo achieves $50m in sales in 20X5. By 31 December 20X5, PharmaCo's sales were $30m, and BioGenix determined it is highly probable the milestone will not be met.

    Finally, BioGenix has a Cash Generating Unit (CGU) that was impairment tested. Carrying amounts: Goodwill $1m, Patent $4m, Equipment $5m. Recoverable amount of the CGU is $7m.

    Question: How much revenue should BioGenix recognize from the PharmaCo licensing agreement for the year ended 31 December 20X5?

    Answer options:

    A.

    $1,000,000

    B.

    $5,000,000

    C.

    $7,000,000

    D.

    $1,400,000

    How to approach this question

    Determine if the license is a 'right to access' (over time) or 'right to use' (point in time). Then apply the constraint on variable consideration for the milestone.

    Full Answer

    B.$5,000,000✓ Correct
    Under IFRS 15, a license providing a 'right to use' intellectual property as it exists at the point in time the license is granted is recognized immediately. Since BioGenix has no further obligations, the $5m is recognized upfront. The $2m milestone is variable consideration; because it is highly probable it will not be met, it is constrained to zero.

    Common mistakes

    Spreading the upfront fee over 5 years, confusing 'right to use' with 'right to access'.
    Question 22All questionsQuestion 24

    Practice the full ACCA FR — Financial Reporting Practice Exam 4

    32 questions · hints · full answers · grading

    Sign up freeTake the exam

    More questions from this exam

    Q01**Section A** Under the IASB's Conceptual Framework for Financial Reporting, which of the follow...MediumQ02**Section A** Cobalt Extraction Co operates a deep-sea mining vessel. The vessel cost $50 millio...MediumQ03**Section A** CloudStream Inc provides a 12-month SaaS subscription to a client for $120,000, pa...HardQ04**Section A** AeroFreight sold a cargo aircraft to a leasing company for its fair value of $40 m...HardQ05**Section A** NeuroTech is developing a new neural-interface device. During the year ended 31 De...Easy
    View all 32 questions →